Bicara Therapeutics Inc. (BCAX) Stock Profile — Insider Trades & Financials

Net Income-$37.4M

EPS$-1.84

Market Cap$1.4B

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Claire Mazumdar Clemon

CEO & Executive Director

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Founded: 2018
Employees: 55
Headquarters: Boston, Massachusetts, United States
Website

⚡

Core Efficiency

ROE?

-9.31%

ROA?

-8.67%

D/E Ratio?

0.07

📊

Profitability Ratios

Current Ratio?

14.58

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 23, 2026 (in 136 days)

Annual Report (10-K) — Based on filing pattern

Aug 23, 2026

Predicted10-K

Mar 30, 2026

10-KQ4 20256d after period end

Nov 10, 2025

10-QQ3 20255d after period end

Aug 12, 2025

10-QQ2 20256d after period end

May 13, 2025

10-QQ1 20255d after period end

Mar 27, 2025

10-KQ4 20243d after period end

Nov 12, 2024

10-QQ3 20244d after period end

Loading company sections...

Bicara Therapeutics Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness